SLC27A2 and renal fibrosis: Inhibition of FATP2 activity attenuates intracellular lipid aggregation lipotoxicity, alleviates the development of renal fibrosis, and it was clearly demonstrated its potential as a therapeutic to address lipotoxic disease.